Company profilePharmaceutical#146 of 1,318 in Pakistan✓ No DRAP alerts

EVEREST PHARMACEUTICALS

Pharmaceutical company · 117 brands · 94 molecules

Ranked #177 of 207 companies in Quinolone Antibacterials

117 registered products 39 pharmaceutical brands 94 distinct molecules 0 DRAP alerts

Company overview

117
registered products
39
pharmaceutical brands
94
distinct molecules
4
therapeutic classes
0
DRAP alerts

EVEREST PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 117 product registrations across 94 distinct molecules. It is the 146th largest registrant in Pakistan by product count, and ranks 177th of 207 in Quinolone Antibacterials. Its portfolio is concentrated in Quinolone Antibacterials and Antivirals For Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Levofloxacin6 brands
Cefixime4 brands
Mecobalamin3 brands
Omeprazole3 brands
Azithromycin3 brands
Escitalopram3 brands
Diclofenac3 brands
Pantoprazole3 brands

Therapeutic classes

Quinolone Antibacterials · 1Antivirals For Systemic Use · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Calcium, Combinations With Vitamin D And Other Drugs · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official4 products · Rs 185.88 – Rs 276.12
Median across source: Rs 237.8

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for EVEREST

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.